Key Takeaways:
The U.S. Food and Drug Administration selected Eli Lilly and Regeneron among seven companies for a pilot program that could cut as many as 14 months off the review timeline for new domestic pharmaceutical manufacturing facilities.
"The PreCheck pilot allows FDA reviewers to begin evaluating facilities while they are still under construction, catching and correcting issues earlier," Benjamin Nichols, an FDA spokesperson, said in a statement cited by CNBC.
The program includes Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin. The FDA estimates the accelerated timeline could save participating companies up to 14 months compared with standard review processes, according to the report.
The initiative comes as the Trump administration pushes to strengthen domestic pharmaceutical supply chains and reduce reliance on overseas manufacturing. For Lilly, faster facility approvals could help expand production capacity for its blockbuster GLP-1 drugs, including Zepbound and Mounjaro, just as Medicare begins covering weight-loss treatments. The agency's PreCheck program will allow regulators to review manufacturing sites in parallel with construction rather than waiting for completion.
The pilot signals a shift in how the FDA approaches facility inspections, moving toward a more collaborative model that could become permanent if successful. Participating companies gain a competitive advantage in bringing new production capacity online, though the program's impact will depend on how many facilities are approved through the streamlined process. Investors will watch for the first PreCheck approvals to gauge whether the timeline savings materialize as projected.
This article is for informational purposes only and does not constitute investment advice.
